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Context: The sexual dimorphism of the somatotroph axis has been documented, but whether the
acromegaly-related metabolic alterations are gender-dependent has never been investigated.
Objective: The aimof the studywas to evaluate the impact of gender on themetabolic parameters
in acromegaly.
Design: We conducted a retrospective, comparative, multicenter study.
Patients: The 307 newly diagnosed acromegalic patients included in the study were grouped by
gender: 157men (aged 48.01 14.28 yr), and 150women (aged 48.67 14.95 yr; ofwhich 77were
premenopausal and 73 postmenopausal).
OutcomeMeasurements:Wemeasured each component of the metabolic syndrome (MS), hemo-
globin A1c, the areas under the curve (AUCs) of glucose and insulin during 2-h oral glucose tol-
erance test, basal insulin resistance using the homeostasis model assessment of the insulin resis-
tance index, stimulated insulin sensitivity using the insulin sensitivity index, early insulin-secretion
rate using the insulinogenic index, -cell function relative to insulin sensitivity using the oral
disposition index and the visceral adiposity index (VAI) as the surrogate of visceral fat function.
Results:Women showed a higher prevalence of MS (P  0.001), higher fasting insulin levels (P 
0.001), AUC for insulin (P  0.002), homeostasis model assessment of the insulin resistance index
(P 0.001), and VAI (P 0.001) and a lower insulin sensitivity index (P 0.002) thanmen, whereas
nodifferencewas found in fasting glucose, AUC for glucose, hemoglobinA1c, insulinogenic index,
andoral disposition index. Inwomen, fastingglucoseand fasting insulin showeda significant trend
toward increase (P  0.001) and decrease (P  0.004), respectively, from the first to the fourth
quartiles of age, whereas VAI showed a trend toward increase in both groups (P  0.001). A
significantly higher prevalence of MS (P  0.001), increased waist circumference (P  0.001), low
high-density lipoprotein cholesterol (P 0.001), and overt diabetesmellitus (P 0.001) was found
in postmenopausal women compared with premenopausal women, as well as with men.
Conclusions: The majority of metabolic features in acromegaly are gender-specific. Active acro-
megaly in women is strongly associated with higher visceral adiposity dysfunction, insulin resis-
tance, and the features of MS. We suggest more accurate metabolic management in acromegalic
women, especially in the postmenopausal years. (J Clin Endocrinol Metab 98: E51–E59, 2013)
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Gender may affect the GH and IGF-I secretory patternboth in healthy subjects and in patients with acro-
megaly through mechanisms not fully understood and
with discordant evidence. Spontaneous GH secretion
seems to be higher in healthy women than in men (1, 2),
whereas IGF-I levels are similar or higher in men (3, 4).
Due to the lower sensitivity toGH,womenaffected byGH
deficiency or hypopituitarism and receiving estrogen re-
placement need a higher GH dose than men to achieve
normal IGF-I levels (5, 6). On the other hand, in acromeg-
aly, higherGHor IGF-I levels havebeen foundboth inmen
and in women in different cohorts of patients analyzed.
Some authors showed lower serum IGF-I levels and IGF-
I/GH ratio in women than in men, particularly in younger
patients, without any difference in GH levels, suggesting
that gender, presumably sex steroids in women, may only
partially modulate the relationship between circulating
IGF-I and GH levels in patients with acromegaly (7). In-
deed, Ede`n Engstro¨m et al. (8) demonstrated that women
with acromegaly need lower doses of octreotide than men
to normalize IGF-I levels.
Conversely, basal GH was found to be higher in de
novowomen than in menwith acromegaly by Colao et al.
(9), and both basal and nadir GH levels were found to be
significantly higher in womenwhenGHwasmeasured by
different immunoassays (10). By contrast, a retrospective
analysis of the data in the German Acromegaly Register,
including 1485 patients, demonstrated significantly
higher GH levels in men than women, and sex was con-
sidered an independent risk factor for biochemical activity
in acromegaly (11). However, although gender has been
consideredby someauthors a relevant determinant of hor-
monal levels in acromegaly, crucial to appropriately eval-
uating the activity of the disease, whether acromegaly-
related metabolic alterations are gender-dependent has
not been investigated so far.
The aim of this study was to evaluate the impact of
gender on hormonal and metabolic parameters in a
large Italian series of newly diagnosed patients with
acromegaly.
Patients and Methods
Patients
We retrospectively reviewed the data from consecutive pa-
tients with active acromegaly recruited and diagnosed at the De-
partments of Endocrinology of the Universities of Palermo, Na-
ples, and Genoa between 2000 and 2010. Of 390 newly
diagnosed patients, 307 (157 men aged 48  14.2 yr, and 150
women aged 48.6  14.9 yr, of which 77 were premenopausal
and 73 were postmenopausal) were included in the study. Ex-
clusion criteria were: mixed GH/prolactin-secreting adenomas,
any previous specific treatment for acromegaly (surgery, soma-
tostatin analogs, dopamine agonist, or radiotherapy), and the
presence of concomitant overt hypogonadism, to avoid the po-
tential impact of hormonal deficit or gonadal replacement ther-
apy on GH, IGF-I, as well as metabolic parameters. No women
receiving estrogens and/or progesterone as contraceptives or
postmenopausal hormone in replacement therapy were in-
cluded. The 157 men and 150 women were divided into the
following groups in line with quartiles of age: first quartile (39
men, 38.5 yr; 41 women, 37 yr), second quartile (45 men,
38.5–49yr; 35women,37–47yr), thirdquartile (38men,50–59
yr; 38 women, 48–63 yr), and fourth quartile (35 men,59 yr;
36 women 63 yr).
Disease activity at the time of the study was confirmed by
altered serum GH during morning profile and/or nonsuppress-
ible GH below 1 g/liter after oral glucose tolerance test
(OGTT), elevated age, and gender-corrected plasma IGF-I levels
(12). In 28 subjects with a previous diagnosis of overt diabetes
mellitus (DM),OGTTwas not performed, and the diagnosiswas
made by high serum GH, calculated as the mean of a 6-h blood
sampling (0800–1400 h with 30-min sampling), IGF-I levels,
and adequate clinical context. As regards hypoglycemic therapy
of the whole cohort of patients, impaired fasting glucose (IFG)
and impaired glucose tolerance (IGT) subjects were treated with
diet alone (68%) or metformin (32%); diabetic patients were
treated with metformin alone (70%) or in combination with
other hypoglycemic drugs (sulfonylureas or glinides) (30%). All
patients with a previous diagnosis of DM, IFG, or IGT and al-
ready receiving dietary or pharmacological therapy suspended
the treatment for at least 3dbeforemetabolic evaluation toavoid
an effect on insulin sensitivity and secretion indexes (13). In all
patients, magnetic resonance imaging revealed the presence of a
pituitary tumor.Tumorvolumewas calculated in linewith theDi
Chiro andNelson formula (volumeheight lengthwidth
/6) and was expressed as cubic millimeters. The mean duration
of the diseasewas established by patient interview, patients’ clin-
ical pictures, and onset of osteoarticular symptoms. At the time
of hospitalization, all patients signed an informed consent for the
scientific use of their data. The identity of the participants re-
mained anonymous during database analysis.
Study design
This is a retrospective, comparative, multicenter cohort
study. All patients at diagnosis underwent complete clinical and
metabolic evaluation. Body mass index (BMI), systolic and di-
astolic blood pressure were measured in all patients. Waist cir-
cumference (WC) was measured at the midpoint between the
lower rib and the iliac crest. Patients were analyzed according to
each criterion of the metabolic syndrome (MS) (14) and each
category of glucose tolerance (15). After an overnight fast, lipid
profile [total, high-density lipoprotein (HDL), and low-
density lipoprotein-cholesterol, triglycerides], hemoglobin A1c
(HbA1c), mean fasting plasma GH (at least three blood samples
at 30-min intervals), and IGF-I levels were measured. To nor-
malize IGF-I for age in individualpatients,wecalculated the ratio
between the IGF-I level and the upper limit of the normal (ULN)
range for age (normal  1), and the data were presented as
IGF-I ULN. OGTT was performed by measuring plasma blood
glucose, insulin levels, and GH every 30 min for 2 h after a 75-g
oral glucose load. The areas under the curve of glucose
(AUCGLU), insulin (AUCINS) and GH (AUCGH) during 2-h
OGTT were calculated. Basal insulin resistance was assessed
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using homeostasis model assessment of the insulin resistance
index (Homa-IR) (16), whereas insulin sensitivity wasmeasured
using the insulin sensitivity index (ISI), a composite indexderived
from the OGTT and validated by Matsuda and DeFronzo (17).
The early insulin-secretion rate was evaluated using the insuli-
nogenic index (18). The total insulin secretion was assessed by
AUCINS,whereas the-cell function relative to insulin sensitivity
was assessed by the oral disposition index (DIo) (19).
As the surrogate of visceral fat function in all patients, we
calculated the visceral adiposity index (VAI), an index of adipose
tissue distribution and function associatedwith cardiometabolic
risk (20) and already demonstrated to be strongly associated
with active acromegaly (21, 22).
VAI was calculated using the following formulas differenti-
ated according to sex, where TG is triglycerides levels expressed
in millimoles per liter and HDL is HDL-cholesterol levels ex-
pressed in millimoles per liter: Males, VAI  [WC/39.68 
(1.88 BMI)] (TG/1.03) (1.31/HDL); and Females, VAI
[WC/36.58  (1.89  BMI)]  (TG/0.81)  (1.52/HDL).
Hormone and biochemical assays
Glycemia, HbA1c, and lipid levels were measured in central-
ized accredited laboratories with standard methods. During the
study period, GH levels were assayed by immunoradiometric
and immunoenzymatic assays according to availability. The sen-
sitivity of the assays ranged from 0.05–0.02 g/liter. Serum
IGF-I wasmeasured using immunoradiometric assays (Diagnos-
tic Systems Laboratories Inc., Webster, TX). The normal ranges
(for age) were: 180–625 and 151–530 (20 yr), 118–475 and
118–450 (21–30 yr), 102–400 and 100–390 (31–40 yr), 100–
306 and 96–228 (41–50 yr), 95–270 and 90–250 (51–60 yr),
88–250 and 82–200 (61–70 yr), and 78–200 and 68–188 g/
liter (70 yr) for men and women, respectively. The sensitivity
of the assay was 0.8 g/liter. The intra- and interassay coeffi-
cients of variation were 3.4, 3.0, and 1.5%, and 8.2, 1.5. and
3.7% for low, medium, and high points on the standard curve,
respectively. Serum insulin was measured by ELISA (DRG In-
struments GmbH, Marburg, Germany). The sensitivity of the
methodwas1 IU/ml.Thenormal insulin range (IU/ml)was5–19.
The assays for the assessment of IGF-I and insulin were constant
during this entire period. We decided to analyze the data of pa-
tients recruited in the decade 2000–2010 because in that period
we did not change assay.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17
(SPSS Inc., Chicago, IL) was used for data analysis. Baseline
characteristics were presented asmean SD for continuous vari-
ables; rates andproportionswere calculated for categorical data.
Normality of distribution for quantitative variableswas assessed
by the Kolmogorov-Smirnov test. Because age, BMI, and AUC-
GLU did not show normal distribution, these variables were log-
transformed. Differences between groups in univariate analysis
were detected by the unpaired Student’s t test for continuous
variables and by the 2 test and Fisher’s exact test (when appro-
priate) for categorical variables.Differences inmetabolic param-
eters between men and women were corrected for AUCGH
through a logistic regressionmodel. The ANOVA trend analysis
was used to assessmeans ofmetabolic and hormonal parameters
across the age quartiles. A P value of 0.05 was considered
statistically significant.
Results
The clinical and biochemical features of all patients,
grouped for gender, are listed in Table 1.
No difference in age (48.01 14.28 vs. 48.67 14.95
yr;P0.693),BMI (25.543.43vs.25.803.59kg/m2;
P  0.512), duration of disease (85.39  66.46 vs.
88.35  68.28 months; P  0.701), and tumor volume
(1664  1699 vs. 2087  2166 mm3; P  0.137) was
observed between men and women.
Biochemical parameters of acromegaly according
to gender
The basal serum GH levels (31.38  24.21 vs. 26.78 
22.26 g/liter; P 0.085), post-OGTTGH nadir (21.66
17.91 vs. 17.98  17.79 g/liter; P  0.081), AUCGH
(31502333 vs.26452328;P0.059), and IGF-IULN
(2.310.79vs.2.430.89;P0.207)didnotsignificantly
differ between men and women. We found a trend toward
decrease on basal GH (P  0.001 and P  0.002, respec-
tively), post-OGTT GH nadir (P  0.001 and P  0.016,
respectively), and AUCGH (P  0.001 and P  0.004, re-
spectively) from the first to the fourth quartile of age in
both men and women. In addition, in women a trend to-
ward decrease in tumor volume from the first to the fourth
quartile of age (P0.013)was found.Nosignificant trend
toward variation in IGF-I levels was found in either group
(P  0.170 and P  0.411 in men and women, respec-
tively). The biochemical parameters of all patients,
grouped for quartiles of age, are listed inTables 2 and3 for
men and women, respectively.
Metabolic parameters of acromegaly according to
gender
MS was found in 107 patients (34.9%), and its preva-
lence was higher in women than in men (51.3 vs. 19.1%;
P  0.001). Sixty-eight (22.1%) patients had increased
WC according to the above-mentioned Adult Treatment
Panel III criteria, 57 (38%) of whomwere women and 11
(7%) were men (P  0.001). Low HDL-cholesterol was
found in 120 (39.1%) patients, 93 (62%) of whom were
women and 27 (17.2%)weremen (P 0.001).No gender
difference was found in the prevalence of hypertriglycer-
idemia (31.2 vs.35.3%;P0.443).A total of 107women
and95men (71.3 vs.60.5%;P0.046) showed increased
systolic blood pressure, whereas no significant difference
was found in theprevalenceof diastolic bloodpressure (46
vs. 40.8%; P  0.355).
A more marked family history for diabetes was shown
in women than in men (48 vs. 33.8%; P 0.011); 153 of
307 patients (49.8%) were classified as having normal
glucose tolerance, 19 (6.2%) as IGT, and 33 (10.7%) as
combined IFG and IGT, without gender difference in the
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prevalence of these categories of glucose tolerance.
Women were more affected by overt DM than men (51.3
vs. 19.1%; P  0.001), whereas men showed a higher
prevalence of IFG (26.8 vs. 17.3%; P  0.047).
Women showed significantly higher fasting insulin lev-
els (21.25  12.08 vs. 15.14  8.95 IU/ml; P  0.001),
AUCINS (9127 4622 vs. 7578 3383; P 0.002), and
Homa-IR (5.08  2.84 vs. 3.59  2.24; P  0.001), and
lower ISI Matsuda (3.05  2.11 vs. 3.85  2.15; P 
0.002) than men. These significances were confirmed
when we corrected the P value for AUCGH. No difference
was found between men and women in fasting glucose
(5.44  0.90 vs. 5.47  0.92 mmol/liter; P  0.755),
AUCGLU (16,3614,324vs.17,1824,931;P0.140),
HbA1c (5.38  1.17 vs. 5.29  1.15%; P  0.349), in-
sulinogenic index (36.18  52.76 vs. 58.43  150.30;
P  0.137), and DIo (3.82  9.90 vs. 3.42  6.83; P 
0.630). Women showed significantly higher VAI value
thanmen (2.51 1.10 vs. 1.58 0.75; P 0.001). This
significance was confirmed when we corrected the P
value for AUCGH.
Analyzing themetabolic parameters according to quar-
tiles of age, no significant trend toward variation in all
parameters was found in men, with the exception of VAI,
which showed a trend toward increase from the first to the
fourth quartile (P0.001) (Fig. 1). Conversely, inwomen
fasting glucose and fasting insulin showed a significant
trend toward increase (P  0.001) and decrease (P 
0.004), respectively (Fig. 2). No significant trend toward
variation in other metabolic parameters was found,
whereasVAI showeda trend toward increase fromthe first
to the fourth quartile (P 0.001) (Fig. 1). The metabolic
parameters of all patients, grouped for quartiles of age, are
listed in Tables 2 and 3 for men and women, respectively.
Whenwe further analyzed each criterion of theMS and
the categories of glucose tolerance, grouping women into
two groups on the basis of the menopausal status, a sig-
nificantly higher prevalence ofMS (P 0.001), increased
WC (P  0.001), low HDL-cholesterol (P  0.001), and
overt DM (P  0.001) was found in postmenopausal
women compared with premenopausal women, as well as
with men. Conversely, a slightly higher prevalence of IFG
TABLE 1. Clinical and biochemical features of 307 newly diagnosed acromegalic patients grouped for gender
All patients Men Women P Pa
n 307 157 150
Age (yr) 48.33  14.59 48.01  14.28 48.67  14.95 0.693
BMI (kg/m2) 25.67  3.51 25.54  3.43 25.80  3.59 0.512
Duration of disease (months) 86.83  67.26 85.39  66.46 88.35  68.28 0.701
Tumor volume (mm3) 1867  1943 1664  1699 2087  2166 0.137
Basal GH (g/liter) 29.13  23.35 31.38  24.21 26.78  22.26 0.085
Nadir GH (g/liter) 19.87  17.91 21.66  17.91 17.98  17.79 0.081
AUCGH 2903  2341 3150  2333 2645  2328 0.059
IGF-I (ULN) 2.37  0.84 2.31  0.79 2.43  0.89 0.207
MS 107 (34.9) 30 (19.1) 77 (51.3) 0.001
Increased WC 68 (22.1) 11 (7) 57 (38) 0.001
Hypertriglyceridemia 102 (33.2) 49 (31.2) 53 (35.3) 0.443
Low HDL-cholesterol 120 (39.1) 27 (17.2) 93 (62) 0.001
Increased systolic blood pressure or specific
treatment
202 (65.8) 95 (60.5) 107 (71.3) 0.046
Increased diastolic blood pressure or specific
treatment
133 (43.3) 64 (40.8) 69 (46) 0.355
Family history for diabetes 125 (40.7) 53 (33.8) 72 (48) 0.011
Normal tolerance 153 (49.8) 80 (51) 73 (48.7) 0.688
IFG 68 (22.1) 42 (26.8) 26 (17.3) 0.047
IGT 19 (6.2) 10 (6.4) 9 (6.0) 0.893
IFG  IGT 33 (10.7) 17 (10.8) 16 (10.7) 0.964
DM 107 (34.9) 30 (19.1) 77 (51.3) 0.001
Fasting glucose (mmol/liter) 5.45  0.91 5.44  0.90 5.47  0.92 0.755
HbA1c (%) 5.32  1.16 5.38  1.17 5.29  1.15 0.349
Fasting insulin (IU/ml) 18.18  11.04 15.14  8.95 21.25  12.08 0.001 0.001
Homa-IR 4.33  2.66 3.59  2.24 5.08  2.84 0.001 0.001
ISI-Matsuda 3.45  2.16 3.85  2.15 3.05  2.11 0.002 0.020
AUCINS 8358  4121 7578  3383 9127  4622 0.002 0.004
AUCGLU 931  259 908  240 954  273 0.140
Insulinogenic index (ns 30 min/Glu 30 min) 47.40  113 36.18  52.76 58.43  150.30 0.137
DIo 3.67  8.47 3.82  9.90 3.42  6.83 0.630
VAI 2.03  1.04 1.58  0.75 2.51  1.10 0.001 0.001
Data are expressed as number of subjects (percentage) or mean  SD.
a P value corrected for AUCGH.
E54 Ciresi et al. Gender-Specific Features in Acromegaly J Clin Endocrinol Metab, January 2013, 98(1):E51–E59
(P  0.006) was found in men. No significant difference
in the prevalence of hypertriglyceridemia (P 0.683), in-
creased systolic (P  0.054) and diastolic (P  0.570)
blood pressure, IGT (P  0.528), and IFG  IGT (P 
0.505) was found among the three groups (Table 4).
In addition, we compared the metabolic features of ac-
romegalic patients with a group of 301 Caucasian healthy
nonacromegalic subjects matched for age and BMI. For
this purpose, we used the collected data from Genoa, Na-
ples, and Palermo. Metabolic parameters were signifi-
cantly poorer in acromegalic patients than in control sub-
jects. Acromegalic men and pre- and postmenopausal
women showed a higher prevalence of hypertriglyceride-
mia, lowHDL-cholesterol, increased systolic anddiastolic
blood pressure, and higher VAI. Acromegalic patients
showed a significantly greater prevalence of DM com-
pared with nonacromegalic subjects. A lesser degree of
insulin sensitivity was also evident in acromegalic pa-
tients regardless of gender, as demonstrated by higher
fasting insulin levels and Homa-IR and by lower ISI-
Matsuda compared with nonacromegalic subjects.
These data are shown in Supplemental Table 1, pub-
TABLE 2. Parameters of disease activity and metabolic features of 157 men with newly diagnosed acromegaly
across quartiles of age
First quartile Second quartile Third quartile Fourth quartile P for trend
n 39 45 38 35
Tumor volume (mm3) 1830  1450 1720  2110 1550  1130 1410  1750 0.352
Basal GH (g/liter) 41.26  22.58 40.16  25.69 17.33  17.39 24.33  21.24 0.001
Nadir GH (g/liter) 26.97  16.29 26.20  17.90 14.76  17.28 16.31  17.14 0.001
AUCGH 3890  2108 3975  2310 1942  2087 2574  2203 0.001
IGF-I (ULN) 2.19  0.42 2.34  0.75 2.20  0.82 2.51  1.07 0.170
Fasting glucose
(mmol/liter)
5.17  0.88 5.56  0.73 5.39  0.71 5.62  1.21 0.077
HbA1c (%) 5.13  0.82 5.36  0.96 5.65  1.75 5.38  0.92 0.216
Fasting insulin (IU/ml) 15.61  7.42 16.82  10.49 11.39  6.29 16.30  10.05 0.558
Homa-IR 3.63  2.09 4.12  2.63 2.65  1.34 3.85  2.40 0.576
ISI-Matsuda 3.33  1.22 3.22  1.22 4.53  2.16 3.19  1.33 0.256
AUCINS 8620  3091 8167  2970 7060  3281 7842  3306 0.126
AUCGLU 956  139 948  195 827  325 944  214 0.251
Insulinogenic index
(ns 30 min/Glu
30 min)
24.47  307.65 67.81  107.35 42.52  46.75 5.45  279.94 0.738
DIo 0.18  9.57 5.57  10.09 7.08  11.09 2.88  6.18 0.101
VAI 1.22  0.38 1.65  0.59 1.48  0.78 1.98  1.00 0.001
Data are expressed as mean  SD.
TABLE 3. Parameters of disease activity and metabolic features of 150 women with newly diagnosed acromegaly
across quartiles of age
First quartile Second quartile Third quartile Fourth quartile P for trend
Tumor volume (mm3) 2720  2500 2,100  1,710 1,990  2,570 940  1000 0.013
Basal GH (g/liter) 30.85  21.17 34.46  20.63 23.82  20.75 17.82  23.60 0.002
Nadir GH (g/liter) 21.87  17.63 20.14  15.68 16.21  17.01 11.84  20.40 0.016
AUCGH 3,171  2,296 3,249  2,163 2,267  2,017 1,857  2,594 0.004
IGF-I (ULN) 2.22  0.66 2.59  0.69 2.55  1.32 2.39  0.69 0.411
Fasting glucose
(mmol/liter)
5.12  0.66 5.07  0.73 5.44  0.81 6.29  0.94 0.001
HbA1c (%) 5.11  0.98 5.35  1.38 5.45  1.44 5.12  0.64 0.817
Fasting insulin (IU/ml) 23.48  12.77 24.84  13.61 20.03  11.05 16.32  8.94 0.004
Homa-IR 5.39  3.06 5.52  3.05 4.82  2.64 4.57  2.55 0.141
ISI-Matsuda 2.77  1.60 2.50  1.02 3.12  1.93 2.58  1.49 0.852
AUCINS 9,631  4,123 10,559  5245 9,247  4,568 8,998  2,521 0.380
AUCGLU 956  216 982  218 962  235 1,068  218 0.087
Insulinogenic index
(ns 30 min/Glu
30 min)
67.45  178.65 40.80  91.11 95.72  206.09 59.87  120.84 0.749
DIo 2.83  5.77 1.36  1.09 5.99  10.59 3.22  4.47 0.204
VAI 2.13  0.80 2.47  0.94 2.47  1.11 3.02  1.34 0.001
Data are expressed as mean  SD.
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lished on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org).
Discussion
In this multicenter retrospective study, we analyzed the
hormonal and metabolic parameters in a large series of
men and women affected by active untreated acromegaly.
Women showed a worse metabolic profile than men, re-
gardless of the hormonal data, indicating that gender
may independently affect the metabolic parameters in
acromegaly.
The sexual dimorphism of the somatotroph axis and
the lower sensitivity to GH in women have already been
documented (23, 24), although with discordant results.
Higher mean GH concentrations have frequently been
found in both healthy and acromegalic women than in
men (1, 7, 8), but these data are not confirmed by other
studies (25). Lower IGF-I levels with concomitant higher
GHnadir duringOGTT have also been documented in 79
newly diagnosed acromegalic women compared with 72
men (4). In contrast with previous studies, some authors
demonstrated higher IGF-I levels in men, because of the
potential androgen role in stimulating GH secretion (26).
Our data, showing a similar hormonal profile in men and
women in terms of basal GH, nadir of GH during OGTT,
AUC of GH and IGF-I levels, are in agreement with those
of Freda et al. (27), which demonstrated in 92 subjects
with acromegaly no significant gender difference in basal
and nadir GH levels, thus not supporting separate criteria
for treatment in men and women with acromegaly.
We found thatGHlevels showeda similar trend toward
decrease from younger to older patients in both sexes, and
these data confirm the evidence that in elderly subjects the
disease seems to be less aggressive in terms of biochemical
parameters. In two previous studies, the severity of acro-
megaly was reported to be milder in elderly patients than
in young ones because it was associated with lower GH
values and smaller tumor at presentation (28, 29). It is
known that GH and IGF-I levels physiologically decrease
with aging (25, 30), and our findings are partially in line
with those ofColao et al. (4) showing that age is negatively
correlated with basal and nadir GH in de novo acrome-
galic patients of both sexes. We also found that the tumor
size did not significantly differ between men and women.
In addition, among women, elderly patients had smaller
adenomas than young patients. These data are in agree-
ment with previous papers showing the maximal tumor
diameter inversely correlated with age in women but not
in men (4).
Beyond the hormonal and tumor parameters, already
thoroughly studied, whether the metabolic alterations in
acromegaly are dependent on gender has never previously
been investigated.
A few years ago, a partial gender dimorphism in body
composition abnormalities in acromegaly was hypothe-
sized, with the evidence that acromegalic males had more
totalmass, leanbodymass, andbonemineral content than
controls and that the anabolic effect of GH on bone re-
FIG. 1. VAI for trend according to quartiles of age in acromegalic
women and men.
FIG. 2. Fasting glucose (top) and fasting insulin (bottom) for trend
according to quartiles of age in acromegalic women and men.
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verted in cured males but not in females (32). For these
reasons, we aimed to compare all MS features, the cate-
gories of glucose tolerance, and all indexes of insulin sen-
sitivity and resistance, grouping the entire cohort of pa-
tients according to gender.
The acromegalic women, although displaying GH and
IGF-I levels similar to men, showed a worse global met-
abolic profile, with a higher overall prevalence ofMS.We
found a lower degree of insulin sensitivity and greater
basal and total hyperinsulinism in women than in men,
demonstrated by lower ISI-Matsuda and higher fasting
and AUCINS levels, regardless of GH levels, whereas no
differencewas found in early and relative insulin secretion
indexes (insulinogenic index and DIo). The BMI, which
was comparable between men and women, did not affect
these data. A possible explanation can be the higher vis-
ceral adipose dysfunction in acromegalic women, shown
by higher VAI, than in men. We recently demonstrated
that active acromegaly is strongly associated with visceral
adiposity dysfunction, andboth somatostatin analogs and
surgical therapieswere able to improve it, asdemonstrated
by the significant VAI decrease after 12 months of treat-
ment (21). In addition, patients with high VAI show de-
creased insulin sensitivity because a significantly strong
associationbetweenVAIand the rateofperipheral glucose
utilization (M value) has been demonstrated (22). There-
fore, the higher VAI levels in women with acromegaly
could lead toa lowerdegreeof insulin sensitivity thanmen.
This finding seems to be in contrast with the well-known
body composition differences between the sexes in the
general population, where men tend to have central fat
distribution and women tend to have peripheral fat dis-
tribution (33, 34). The higher visceral adiposity observed
in healthy men is associated with elevated postprandial
insulin, free fatty acid, and triglyceride levels (35). Con-
versely, the peripheral fat distribution typically found in
healthy women is associated with improved insulin sen-
sitivity, compared with central fat distribution (36). Ac-
cording to our results, women with acromegaly seem to
have different behavior, in terms of visceral adiposity,
comparedwith the existing data about healthy women. In
our previous paper, although patients with high VAIwere
less insulin-sensitive, no significant difference in the glu-
cose tolerance categories was reported between patients
with normal and highVAI, supporting the hypothesis that
VAI shows the early signs of metabolic risk, although a
significant reduction in glucose tolerance has not yet oc-
curred (22). This finding is apparently in contrast with
these data because women showed a higher prevalence of
overt DM. To explain this apparent discrepancy, the role
of the higher family history for diabetes shown in women
cannot be ruled out. Indeed, a direct and independent in-
fluence by family history for diabetes in VAI has already
been demonstrated (22). Conversely, men only showed a
higher prevalence of IFG, which disappeared when com-
pared with women grouped according tomenopausal sta-
tus. In this connection, the fact that about half of the
women were in the postmenopausal age group must be
taken into account. Postmenopausal age in the general
population is known to be associated with a higher prev-
alence of hypertension, diabetes, lipid alterations, and car-
diovascular disease, likely due to the coincident increase in
insulin resistance and in abdominal adiposity (37–44).
Accordingly, a majority of postmenopausal women com-
ply with the criteria defining MS, and cardiovascular dis-
ease is the first causeofmorbidity andmortality inwomen,
occurring even more frequently than in men (45). Simi-
larly, when we grouped women in line with menopausal
status, a higher prevalence of MS, increased WC, low
HDL-cholesterol, and overt DMwas found in postmeno-
pausal women.Whether these changes are due to aging or
to menopause itself is unknown. In this connection, age
seems to influence metabolic parameters in acromegaly
more in women than in men. The evidence that fasting
TABLE 4. MS and glucose tolerance categories in men and pre- and postmenopausal women
Men Premenopausal women Postmenopausal women P
n 157 77 73
MS 30 (19.1) 31 (40.3) 46 (63) 0.001
Increased WC 11 (7) 22 (28.6) 35 (47.9) 0.001
Hypertriglyceridemia 49 (31.2) 26 (33.8) 27 (37) 0.683
Low HDL-cholesterol 27 (17.2) 46 (59.7) 47 (64.4) 0.001
Increased systolic blood pressure
or specific treatment
95 (60.5) 51 (66.2) 56 (76.7) 0.054
Increased diastolic blood pressure
or specific treatment
64 (40.8) 37 (48.1) 32 (43.8) 0.570
IFG 42 (26.8) 7 (9.1) 19 (26) 0.006
IGT 10 (6.4) 3 (3.9) 6 (8.2) 0.528
IFG  IGT 17 (10.8) 6 (7.8) 10 (13.7) 0.505
DM 8 (5.1) 7 (9.1) 19 (26) 0.001
Data are expressed as number of subjects (percentage).
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glucose showed a trend toward increase parallel to age
increase in women only, together with a trend toward a
decrease in fasting insulin, could be associated with the
trend toward increase in VAI from the first to the fourth
quartile of age, mainly in women. The visceral adipose
dysfunction seems to act on basal insulin secretion and
consequently on hepatic glucose output. In this connec-
tion, the increase in visceral adipose tissue is reported to
contribute to enhanced gluconeogenesis and insulin resis-
tance (46, 47). Therefore, in agreement with these find-
ings, the higher VAI values in women could explain this
different trend in the two groups of patients. In addition,
a role of the mammalian target of rapamycin (mTOR)
pathway, known to promote hyperinsulinism and insulin
resistance and, by a feedback loop, to be overactivated by
insulin and other growth factors, cannot be ruled out (48–
50). In fact, a stronger activation of mTOR signaling in
women than in men was recently demonstrated (31).
Therefore, a more pronounced activation of mTOR path-
way in women that could favor a greater degree of insulin
resistance is not to be ruled out.
In conclusion, these data demonstrated that the major-
ity of metabolic features in acromegaly are gender-spe-
cific, regardless of hormonal parameters. Active acromeg-
aly in women is strongly associated with higher visceral
adiposity dysfunction, insulin resistance, and the features
of MS. Therefore, more careful metabolic management is
suggested in acromegalic women. In addition, increased
attention to risk factor modification in the postmeno-
pausal years can help prospectively reduce cardiovascular
disease risk in women with acromegaly.
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